Interestingly, patients with IgA nephropathy (that have been demonstrated to present with high PTX3 levels) were highly represented among those non-diabetic CKD patients that showed a SGLT2i-mediated benefit [6]. Here, PTX3 is linked to IgA glomerulonephritis.